Please assess the completion status of the following clinical trial:

Trial Title: Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with head and neck cancer who are undergoing either flap or nonflap surgery (limited to parotidectomy, hard palate maxillectomy and glossectomy, mandibulectomy, and any procedure with neck dissection) at MD Anderson Cancer Center.~2. Patients \> 18 years old.~3. Patients who have not undergone surgery in the past 6 months. Patients may have had neoadjuvant chemotherapy prior to surgery.~4. Patients must have normal renal function test and no prior renal disease. The screening cut off for serum creatinine is \< 1.5mg/dL.~5. Patients must have normal hepatic function test and no prior liver disease: (1) The screening results for alanine aminotransferase (ALT) must be \< 2 times the upper limit of normal. (2) The screening results for aspartate aminotransferase (AST), if available, must be \< 2 times the upper limit of normal.~6. Patients who speak English or Spanish (due to the novel research and its complexity, we are only accruing English-speaking or Spanish-speaking patients to the protocol).~7. Patients must be willing and able to review, understand, and provide written consent.~8. Patients must be willing to discontinue taking dong quai and/or St. John's wort.~Exclusion Criteria:~1. Patients who are taking medications (including minocycline) or have conditions that potentially preclude use of the study medication or intervention as determined by the treating physician.~2. Patients who are enrolled in another symptom management trial or receiving active treatment under another clinical trial.~3. Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of the anesthetics or analgesics medications used in the study.~4. Patients with hypersensitivity to any tetracycline.~5. Patients on vitamin K antagonist (i.e., warfarin).~6. Patients taking any tetracycline within the last 15 days.~7. Patients who have been on opioid therapy for the last 4 weeks or more.~8. Patients with bile duct obstruction.~9. Patients who are pregnant.~10. Patients with INR \> 1.5.~11. Patients with autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: EXPERIMENTAL): Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
- Placebo (Type: PLACEBO_COMPARATOR): Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues